{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:14Z","timestamp":1792801934457,"version":"4.5.0"},"reference-count":133,"publisher":"Galenos Yayinevi","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkiye Parazitol Derg"],"published-print":{"date-parts":[[2022,9,12]]},"DOI":"10.4274\/tpd.galenos.2022.14633","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T06:31:42Z","timestamp":1662964302000},"page":"224-227","source":"Crossref","is-referenced-by-count":4,"title":["Investigation of the Characteristics of Crimean Congo Hemorrhagic Fever Cases Reported in Afyonkarahisar Province"],"prefix":"10.4274","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7236-2164","authenticated-orcid":false,"given":"Derya","family":"Korkmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-1220","authenticated-orcid":false,"given":"Petek","family":"Konya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6186-2494","authenticated-orcid":false,"given":"Ne\u015fe","family":"Demirt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"issue":"2","key":"ref0","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s13105-019-00675-7","article-title":"FGF19 subfamily members: FGF19 and FGF21","volume":"75","author":"Dolegowska","year":"2019","unstructured":"1. Dolegowska K, Marchelek-Mysliwiec M, Nowosiad-Magda M, Slawinski M, Dolegowska B. FGF19 subfamily members: FGF19 and FGF21. Journal of Physiology and Biochemistry. 2019;75(2):229-40.","journal-title":"Journal of Physiology and Biochemistry"},{"issue":"11","key":"ref1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/a-0879-2968","article-title":"Circulating FGF21 Levels in Human Health and Metabolic Disease","volume":"128","author":"Keuper","year":"2019","unstructured":"2. Keuper M, H\u00e4ring H-U, Staiger H. Circulating FGF21 Levels in Human Health and Metabolic Disease. Experimental and Clinical Endocrinology & Diabetes. 2019;128(11):752-70.","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"issue":"3","key":"ref2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic Messengers: FGF21","volume":"3","author":"KH","year":"2021","unstructured":"3. Flippo KH, Potthoff MJ. Metabolic Messengers: FGF21. Nat Metab. 2021;3(3):309-17.","journal-title":"Nat Metab"},{"issue":"11","key":"ref3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","unstructured":"4. Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nature Reviews Endocrinology. 2020;16(11):654-67.","journal-title":"Nature Reviews Endocrinology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fphys.2019.00419","article-title":"FGF21 as Modulator of Metabolism in Health and Disease","volume":"10","author":"Tezze","year":"2019","unstructured":"5. Tezze C, Romanello V, Sandri M. FGF21 as Modulator of Metabolism in Health and Disease. Front Physiol. 2019;10:419.","journal-title":"Front Physiol"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrendo.2016.206","article-title":"FGF21 and metabolic disease in 2016: A new frontier in FGF21 biology","volume":"13","author":"Potthoff","year":"2017","unstructured":"6. Potthoff MJ. FGF21 and metabolic disease in 2016: A new frontier in FGF21 biology. Nat Rev Endocrinol. 2017;13(2):74-6.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11154-019-09488-x","article-title":"The roles of FGF21 in atherosclerosis pathogenesis","volume":"20","author":"Tabari","year":"2019","unstructured":"7. Tabari FS, Karimian A, Parsian H, Rameshknia V, Mahmoodpour A, Majidinia M, et al. The roles of FGF21 in atherosclerosis pathogenesis. Rev Endocr Metab Disord. 2019;20(1):103-14.","journal-title":"Rev Endocr Metab Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2020.03.009","article-title":"Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease","volume":"299","author":"Tucker","year":"2020","unstructured":"8. Tucker B, McClelland RL, Allison MA, Budoff MJ, Wu BJ, Barter PJ, et al. Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease. Atherosclerosis. 2020;299:38-44.","journal-title":"Atherosclerosis"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving Role for Pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","unstructured":"9. Attia SL, Softic S, Mouzaki M. Evolving Role for Pharmacotherapy in NAFLD\/NASH. Clin Transl Sci. 2021;14(1):11-9.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"ref9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543784.2020.1718104","article-title":"Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)","volume":"29","author":"Ritchie","year":"2020","unstructured":"10. Ritchie M, Hanouneh IA, Noureddin M, Rolph T, Alkhouri N. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? Expert Opinion on Investigational Drugs. 2020;29(2):197-204.","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"3","key":"ref10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.14218\/JCTH.2017.00056","article-title":"Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials","volume":"6","author":"Connolly","year":"2018","unstructured":"11. Connolly JJ, Ooka K, Lim JK. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. J Clin Transl Hepatol. 2018;6(3):264-75.","journal-title":"J Clin Transl Hepatol"},{"issue":"10165","key":"ref11","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","unstructured":"12. Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet. 2018;392(10165):2705-17.","journal-title":"The Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases","volume":"11","author":"EJ","year":"2020","unstructured":"13. Tillman EJ, Rolph T. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front Endocrinol (Lausanne). 2020;11:601290.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"30484","DOI":"10.1038\/srep30484","article-title":"Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL\/6J mice","volume":"6","author":"Rusli","year":"2016","unstructured":"14. Rusli F, Deelen J, Andriyani E, Boekschoten MV, Lute C, van den Akker EB, et al. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL\/6J mice. Sci Rep. 2016;6:30484.","journal-title":"Sci Rep"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2478\/jtim-2019-0029","article-title":"Role of Hepatokines in Non-alcoholic Fatty Liver Disease","volume":"7","author":"Ke","year":"2019","unstructured":"15. Ke Y, Xu C, Lin J, Li Y. Role of Hepatokines in Non-alcoholic Fatty Liver Disease. J Transl Int Med. 2019;7(4):143-8.","journal-title":"J Transl Int Med"},{"issue":"8","key":"ref15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","unstructured":"16. Keinicke H, Sun G, Mentzel CMJ, Fredholm M, John LM, Andersen B, et al. FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation. Endocr Connect. 2020;9(8):755-68.","journal-title":"Endocr Connect"},{"key":"ref16","unstructured":"17. Lee JH. An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. Am J Transl Res. 2016;8(11):4750-63."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Zhu S, Wu Y, Ye X, Ma L, Qi J, Yu D, et al. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. Mol Cell Biochem. 2016;420(1-2):107-19.","DOI":"10.1007\/s11010-016-2774-2"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cytogfr.2017.08.001","article-title":"Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage","volume":"38","author":"Luo","year":"2017","unstructured":"19. Luo Y, Ye S, Chen X, Gong F, Lu W, Li X. Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. Cytokine & Growth Factor Reviews. 2017;38:59-65.","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"7","key":"ref19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","unstructured":"20. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411-28.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"27","key":"ref20","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.3748\/wjg.14.4300","article-title":"Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis","volume":"14","author":"A-I","year":"2008","unstructured":"21. Gomaa A-I, Khan S-A, Toledano M-B, Waked I, Taylor-Robinson S-D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14(27):4300-8.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"ref21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-019-0806-6","article-title":"Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer","volume":"12","author":"Wang","year":"2019","unstructured":"22. Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12(1):133-.","journal-title":"J Hematol Oncol"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Liu ZY, Luo Y, Fang AP, Wusiman M, He TT, Liu XZ, et al. High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: A prospective cohort study. Liver Int. 2021.","DOI":"10.1111\/liv.15100"},{"issue":"1","key":"ref23","doi-asserted-by":"publisher","first-page":"16482","DOI":"10.1038\/s41598-017-16312-6","article-title":"Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases","volume":"7","author":"Wu","year":"2017","unstructured":"24. Wu L, Pan Q, Wu G, Qian L, Zhang J, Zhang L, et al. Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases. Sci Rep. 2017;7(1):16482.","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-230X-13-67","article-title":"Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress","volume":"13","author":"Yang","year":"2013","unstructured":"25. Yang C, Lu W, Lin T, You P, Ye M, Huang Y, et al. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol. 2013;13:67.","journal-title":"BMC Gastroenterol"},{"key":"ref25","unstructured":"26. Liu X, Zhang P, Martin RC, Cui G, Wang G, Tan Y, et al. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. Am J Cancer Res. 2016;6(5):1011-25."},{"key":"ref26","unstructured":"27. Zhang Q, Li Y, Liang T, Lu X, Liu X, Zhang C, et al. Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation. Am J Cancer Res. 2015;5(5):1762-74."},{"key":"ref27","unstructured":"28. Nan Y, Xiang L, Zhang W, Guo Y, Cao J. [FGF21 inhibits lipid accumulation and inflammation induced by palmitate in human hepatocytes via SIRT1 pathway]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019;35(7):606-12."},{"issue":"22","key":"ref28","doi-asserted-by":"publisher","first-page":"9923","DOI":"10.7150\/thno.45988","article-title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","volume":"10","author":"Zheng","year":"2020","unstructured":"29. Zheng Q, Martin RC, Shi X, Pandit H, Yu Y, Liu X, et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics. 2020;10(22):9923-36.","journal-title":"Theranostics"},{"issue":"12","key":"ref29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/mc.20241","article-title":"Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis","volume":"45","author":"Huang","year":"2006","unstructured":"30. Huang X, Yu C, Jin C, Yang C, Xie R, Cao D, et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog. 2006;45(12):934-42.","journal-title":"Mol Carcinog"},{"issue":"1","key":"ref30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","unstructured":"31. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-71.","journal-title":"J Hepatol"},{"issue":"12","key":"ref31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/abbs\/gmu097","article-title":"FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway","volume":"46","author":"Zhu","year":"2014","unstructured":"32. Zhu S, Ma L, Wu Y, Ye X, Zhang T, Zhang Q, et al. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochim Biophys Sin (Shanghai). 2014;46(12):1041-8.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref32","unstructured":"33. Zhu SL, Zhang ZY, Ren GP, Ye XL, Ma L, Yu D, et al. [Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism]. Yao Xue Xue Bao. 2013;48(12):1778-84."},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects","volume":"23","author":"Talukdar","year":"2016","unstructured":"34. Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, et al. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell Metabolism. 2016;23(3):427-40.","journal-title":"Cell Metabolism"},{"issue":"28","key":"ref34","doi-asserted-by":"publisher","first-page":"12553","DOI":"10.1073\/pnas.1006962107","article-title":"Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway","volume":"107","author":"Chau","year":"2010","unstructured":"35. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A. 2010;107(28):12553-8.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the Physiology of FGF21","volume":"78","author":"Fisher","year":"2016","unstructured":"36. Fisher FM, Maratos-Flier E. Understanding the Physiology of FGF21. Annual Review of Physiology. 2016;78(1):223-41.","journal-title":"Annual Review of Physiology"},{"issue":"8","key":"ref36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.tem.2019.05.007","article-title":"Going Back to the Biology of FGF21: New Insights","volume":"30","author":"Lewis","year":"2019","unstructured":"37. Lewis JE, Ebling FJP, Samms RJ, Tsintzas K. Going Back to the Biology of FGF21: New Insights. Trends Endocrinol Metab. 2019;30(8):491-504.","journal-title":"Trends Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Itoh N, Nakayama Y, Konishi M. Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease. Frontiers in Cell and Developmental Biology. 2016;4.","DOI":"10.3389\/fcell.2016.00030"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cca.2019.08.005","article-title":"Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease","volume":"498","author":"Su","year":"2019","unstructured":"39. Su X, Kong Y, Peng D. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. Clinica Chimica Acta. 2019;498:30-7.","journal-title":"Clinica Chimica Acta"},{"issue":"3","key":"ref39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","article-title":"FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues","volume":"23","author":"Schlein","year":"2016","unstructured":"40. Schlein C, Talukdar S, Heine M, Fischer Alexander W, Krott Lucia M, Nilsson Stefan K, et al. FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues. Cell Metabolism. 2016;23(3):441-53.","journal-title":"Cell Metabolism"},{"issue":"1","key":"ref40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41598-018-37198-y","article-title":"Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure","volume":"9","author":"Ameka","year":"2019","unstructured":"41. Ameka M, Markan KR, Morgan DA, BonDurant LD, Idiga SO, Naber MC, et al. Liver Derived FGF21 Maintains Core Body Temperature During Acute Cold Exposure. Sci Rep. 2019;9(1):630.","journal-title":"Sci Rep"},{"issue":"10","key":"ref41","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1210\/jc.2017-01257","article-title":"FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans","volume":"102","author":"Samms","year":"2017","unstructured":"42. Samms RJ, Lewis JE, Norton L, Stephens FB, Gaffney CJ, Butterfield T, et al. FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans. J Clin Endocrinol Metab. 2017;102(10):3806-13.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 Regulates Sweet and Alcohol Preference","volume":"23","author":"Talukdar","year":"2016","unstructured":"43. Talukdar S, Owen BM, Song P, Hernandez G, Zhang Y, Zhou Y, et al. FGF21 Regulates Sweet and Alcohol Preference. Cell Metab. 2016;23(2):344-9.","journal-title":"Cell Metab"},{"issue":"46","key":"ref43","doi-asserted-by":"publisher","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","unstructured":"44. Baruch A, Wong C, Chinn LW, Vaze A, Sonoda J, Gelzleichter T, et al. Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans. Proceedings of the National Academy of Sciences. 2020;117(46):28992-9000.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"ref44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000367943","article-title":"The single nucleotide polymorphism rs499765 is associated with fibroblast growth factor 21 and nonalcoholic fatty liver disease in a Chinese population with normal glucose tolerance","volume":"7","author":"Jiang","year":"2014","unstructured":"45. Jiang S, Zhang R, Li H, Fang Q, Jiang F, Hou X, et al. The single nucleotide polymorphism rs499765 is associated with fibroblast growth factor 21 and nonalcoholic fatty liver disease in a Chinese population with normal glucose tolerance. Lifestyle Genomics. 2014;7(3):121-9.","journal-title":"Lifestyle Genomics"},{"key":"ref45","unstructured":"46. Elsayed A. A Polymorphism in the FGF21 Gene is a Novel Risk Variant for Metabolic-Associated Steatohepatitis: University of Sydney; 2020."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. S\u00f8berg S, Sandholt CH, Jespersen NZ, Toft U, Madsen AL, von Holstein-Rathlou S, et al. FGF21 Is a Sugar-Induced Hormone Associated with Sweet Intake and Preference in Humans. Cell Metab. 2017;25(5):1045-53.e6.","DOI":"10.1016\/j.cmet.2017.04.009"},{"issue":"4","key":"ref47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/biomedicines9040345","article-title":"The Effect of FGF21 and Its Genetic Variants on Food and Drug Cravings, Adipokines and Metabolic Traits","volume":"9","author":"Epperlein","year":"2021","unstructured":"48. Epperlein S, Gebhardt C, Rohde K, Chakaroun R, Patt M, Schamarek I, et al. The Effect of FGF21 and Its Genetic Variants on Food and Drug Cravings, Adipokines and Metabolic Traits. Biomedicines. 2021;9(4):345.","journal-title":"Biomedicines"},{"issue":"2","key":"ref48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.celrep.2018.03.070","article-title":"A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure","volume":"23","author":"Frayling","year":"2018","unstructured":"49. Frayling TM, Beaumont RN, Jones SE, Yaghootkar H, Tuke MA, Ruth KS, et al. A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. Cell Rep. 2018;23(2):327-36.","journal-title":"Cell Rep"},{"issue":"9","key":"ref49","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1515\/jpem-2018-0546","article-title":"Association of the 3'UTR polymorphism (rs11665896) in the FGF21 gene with metabolic status and nutrient intake in children with obesity","volume":"32","author":"Ruiz-Padilla","year":"2019","unstructured":"50. Ruiz-Padilla AJ, Morales-Hernandez G, Ruiz-Noa Y, Alonso-Castro AJ, Lazo-de-la-Vega-Monroy ML, Preciado-Puga MDC, et al. Association of the 3'UTR polymorphism (rs11665896) in the FGF21 gene with metabolic status and nutrient intake in children with obesity. J Pediatr Endocrinol Metab. 2019;32(9):921-8.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"11","key":"ref50","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2337\/dc16-1111","article-title":"Macronutrient Intake-Associated FGF21 Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial","volume":"39","author":"Heianza","year":"2016","unstructured":"51. Heianza Y, Ma W, Huang T, Wang T, Zheng Y, Smith SR, et al. Macronutrient Intake-Associated FGF21 Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial. Diabetes Care. 2016;39(11):1909-14.","journal-title":"Diabetes Care"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"9387358","DOI":"10.1155\/2019\/9387358","article-title":"Genetic Variants Flanking the FGF21 Gene Were Associated with Renal Function in Chinese Patients with Type 2 Diabetes","volume":"2019","author":"Yu","year":"2019","unstructured":"52. Yu W, Zhu H, Chen X, Gu X, Zhang X, Shen F, et al. Genetic Variants Flanking the FGF21 Gene Were Associated with Renal Function in Chinese Patients with Type 2 Diabetes. J Diabetes Res. 2019;2019:9387358.","journal-title":"J Diabetes Res"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53. Xu J, Wu F, Wang F, Yang F, Liu M, Lou M, et al. The interaction of single nucleotide polymorphisms on fibroblast growth factor 19 superfamily genes is associated with alcohol dependence-related aggression. Frontiers in genetics. 2021;12.","DOI":"10.3389\/fgene.2021.695835"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54. Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M, et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One. 2011;6(9):e24895.","DOI":"10.1371\/journal.pone.0024895"},{"issue":"1","key":"ref54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.yexcr.2017.05.006","article-title":"Fatty liver and FGF21 physiology","volume":"360","author":"Maratos-Flier","year":"2017","unstructured":"55. Maratos-Flier E. Fatty liver and FGF21 physiology. Experimental Cell Research. 2017;360(1):2-5.","journal-title":"Experimental Cell Research"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56. Liu Z, Luo Y, Fang A, Wusiman M, He T, Liu X, et al. High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: a prospective cohort study. Liver International. 2021.","DOI":"10.1111\/liv.15100"},{"issue":"1","key":"ref56","doi-asserted-by":"publisher","first-page":"14578","DOI":"10.1038\/s41598-020-71569-8","article-title":"Genome-wide association study for circulating fibroblast growth factor 21 and 23","volume":"10","author":"G-T","year":"2020","unstructured":"57. Chuang G-T, Liu P-H, Chyan T-W, Huang C-H, Huang Y-Y, Lin C-H, et al. Genome-wide association study for circulating fibroblast growth factor 21 and 23. Scientific Reports. 2020;10(1):14578.","journal-title":"Scientific Reports"},{"issue":"5","key":"ref57","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1053\/j.gastro.2009.01.050","article-title":"Heritability of nonalcoholic fatty liver disease","volume":"136","author":"Schwimmer","year":"2009","unstructured":"58. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136(5):1585-92.","journal-title":"Gastroenterology"},{"issue":"7","key":"ref58","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","author":"Loomba","year":"2015","unstructured":"59. Loomba R, Schork N, Chen C-H, Bettencourt R, Bhatt A, Ang B, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology. 2015;149(7):1784-93.","journal-title":"Gastroenterology"},{"key":"ref59","unstructured":"60. Griswold M, Fullman N, Hawley C, Arian N. M Zimsen. SR, Tymeson, HD, Venkateswaran, V, Douglas Tapp, A, Forouzanfar, M, Salama, J, Hassen, K, Abate, D, Abay, SM, Abbafati, C, Suliankatchi Abdulkader, R, Abebe, Z, Aboyans, V, Mehdi Abrar, M, Acharya, P,\u2026 Collaborators, A. 2018:1990-2016."},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61. 61. Mitra S. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol2 2020.","DOI":"10.21037\/tgh.2019.09.08"},{"issue":"1","key":"ref61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Arsani","year":"2019","unstructured":"62. Arsani S. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-71.","journal-title":"J Hepatol"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63. Rehm J. Global burden of alcoholic liver diseases. J Hepatol. 2013:160-8.","DOI":"10.1016\/j.jhep.2013.03.007"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64. Tapper E. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study BMJ 2018.","DOI":"10.1136\/bmj.k2817"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Becker U. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology. 2002.","DOI":"10.1053\/jhep.2002.32101"},{"key":"ref65","unstructured":"66. Yamanaka T. Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis. Anticancer Res. 2001:2937-40."},{"issue":"12","key":"ref66","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/abbs\/gmu097","article-title":"FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway","volume":"46","author":"Zhu","year":"2014","unstructured":"67. Zhu S. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochim Biophys Sin (Shanghai). 2014;46(12):1041-8.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"ref67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.alcohol.2004.07.008","article-title":"Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis","volume":"34","author":"Lieber","year":"2004","unstructured":"68. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004;34(1):9-19.","journal-title":"Alcohol"},{"issue":"3","key":"ref68","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s40211-020-00380-8","article-title":"Association of fibroblast growth factor 21 with alcohol consumption and alcohol liver cirrhosis","volume":"35","author":"Wagner-Skacel","year":"2021","unstructured":"69. Wagner-Skacel J, Horvath A, Grande P, Wenninger J, Matzer F, Fazekas C, et al. Association of fibroblast growth factor 21 with alcohol consumption and alcohol liver cirrhosis. Neuropsychiatr. 2021;35(3):140-6.","journal-title":"Neuropsychiatr"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","article-title":"FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest","volume":"11","author":"Soberg","year":"2018","unstructured":"70. Soberg S, Andersen ES, Dalsgaard NB, Jarlhelt I, Hansen NL, Hoffmann N, et al. FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. Mol Metab. 2018;11:96-103.","journal-title":"Mol Metab"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"31026","DOI":"10.1038\/srep31026","article-title":"Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury","volume":"6","author":"Liu","year":"2016","unstructured":"71. Liu Y, Zhao C, Xiao J, Liu L, Zhang M, Wang C, et al. Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. Sci Rep. 2016;6:31026.","journal-title":"Sci Rep"},{"issue":"11","key":"ref71","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.molmet.2017.08.004","article-title":"Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury","volume":"6","author":"Desai","year":"2017","unstructured":"72. Desai BN, Singhal G, Watanabe M, Stevanovic D, Lundasen T, Fisher FM, et al. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol Metab. 2017;6(11):1395-406.","journal-title":"Mol Metab"},{"issue":"6","key":"ref72","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/j.gastro.2004.09.049","article-title":"The role of AMP-activated protein kinase in the action of ethanol in the liver","volume":"127","author":"You","year":"2004","unstructured":"73. You M. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 2004;127(6):1798-808.","journal-title":"Gastroenterology"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"74. Garc\u00eda-Villafranca J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie. 2008;90(3):460-6. .","DOI":"10.1016\/j.biochi.2007.09.019"},{"issue":"28","key":"ref74","doi-asserted-by":"publisher","first-page":"12553","DOI":"10.1073\/pnas.1006962107","article-title":"Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway","volume":"107","author":"Chau","year":"2010","unstructured":"75. Chau M. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A. 2010;107(28):12553-8.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref75","unstructured":"76. Zhu S. Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism. 2013;48(12):1778-84."},{"issue":"7","key":"ref76","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1210\/mend.14.7.0470","article-title":"Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray","volume":"14","author":"Feng","year":"2000","unstructured":"77. Feng X. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol. 2000;14(7):947-55.","journal-title":"Mol Endocrinol"},{"issue":"37","key":"ref77","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","unstructured":"78. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282(37):26687-95.","journal-title":"J Biol Chem"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fendo.2018.00485","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches","volume":"9","author":"KH","year":"2018","unstructured":"79. Kim KH, Lee MS. Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. Front Endocrinol (Lausanne). 2018;9:485.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"ref79","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41598-017-05257-5","article-title":"Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease","volume":"7","author":"Wu","year":"2017","unstructured":"80. Wu G, Li H, Fang Q, Zhang J, Zhang M, Zhang L, et al. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. Sci Rep. 2017;7(1):5095.","journal-title":"Sci Rep"},{"issue":"2","key":"ref80","doi-asserted-by":"publisher","first-page":"215","DOI":"10.14218\/JCTH.2020.00014","article-title":"NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States","volume":"8","author":"Gadiparthi","year":"2020","unstructured":"81. Gadiparthi C, Spatz M, Greenberg S, Iqbal U, Kanna S, Satapathy SK, et al. NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. J Clin Transl Hepatol. 2020;8(2):215-21.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"ref81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","unstructured":"82. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nature Reviews Disease Primers. 2018;4(1):16.","journal-title":"Nature Reviews Disease Primers"},{"issue":"17","key":"ref82","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2019.2276","article-title":"Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016","volume":"321","author":"Wong","year":"2019","unstructured":"83. Wong T, Dang K, Ladhani S, Singal AK, Wong RJ. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016. Jama. 2019;321(17):1723-5.","journal-title":"Jama"},{"issue":"3","key":"ref83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis","volume":"41","author":"Zarei","year":"2020","unstructured":"84. Zarei M, Pizarro-Delgado J, Barroso E, Palomer X, Vazquez-Carrera M. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Trends Pharmacol Sci. 2020;41(3):199-208.","journal-title":"Trends Pharmacol Sci"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"9729107","DOI":"10.1155\/2017\/9729107","article-title":"Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"2017","author":"He","year":"2017","unstructured":"85. He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, et al. Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. BioMed Research International. 2017;2017:9729107.","journal-title":"BioMed Research International"},{"issue":"8","key":"ref85","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","unstructured":"86. Wong VW, Adams LA, de Ledinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-78.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"ref86","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/1751-2980.12384","article-title":"Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease","volume":"17","author":"FF","year":"2016","unstructured":"87. Shen FF, Lu LG. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease. J Dig Dis. 2016;17(9):565-71.","journal-title":"J Dig Dis"},{"issue":"4","key":"ref87","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41401-019-0321-x","article-title":"Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy","volume":"41","author":"Qian","year":"2020","unstructured":"88. Qian LL, Wu L, Zhang L, Zhang J, Zhou J, Li YH, et al. Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. Acta Pharmacol Sin. 2020;41(4):554-60.","journal-title":"Acta Pharmacol Sin"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"89. Luo Y. Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. Cytokine & growth factor reviews. 2017 59-65.","DOI":"10.1016\/j.cytogfr.2017.08.001"},{"issue":"2","key":"ref89","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","unstructured":"90. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139(2):456-63.","journal-title":"Gastroenterology"},{"issue":"1","key":"ref90","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/s41598-017-05257-5","article-title":"Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease","volume":"7","author":"Wu","year":"2017","unstructured":"91. Wu G, Li H, Fang Q, Zhang J, Zhang M, Zhang L, et al. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. Scientific Reports. 2017;7(1):5095.","journal-title":"Scientific Reports"},{"issue":"11","key":"ref91","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1055\/a-0879-2968","article-title":"Circulating FGF21 levels in human health and metabolic disease","volume":"128","author":"Keuper","year":"2020","unstructured":"92. Keuper M, H\u00e4ring H-U, Staiger H. Circulating FGF21 levels in human health and metabolic disease. Experimental and Clinical Endocrinology & Diabetes. 2020;128(11):752-70.","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"issue":"2","key":"ref92","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543784.2020.1718104","article-title":"Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)","volume":"29","author":"Ritchie","year":"2020","unstructured":"93. Ritchie M, Hanouneh IA, Noureddin M, Rolph T, Alkhouri N. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? Expert Opin Investig Drugs. 2020;29(2):197-204.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"ref93","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41467-020-14384-z","article-title":"Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase","volume":"11","author":"Byun","year":"2020","unstructured":"94. Byun S, Seok S, Kim YC, Zhang Y, Yau P, Iwamori N, et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat Commun. 2020;11(1):807.","journal-title":"Nat Commun"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/JHC.S44381","article-title":"Hepatocellular carcinoma: epidemiology and risk factors","volume":"1","author":"Kew","year":"2014","unstructured":"95. Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma. 2014;1:115-25.","journal-title":"J Hepatocell Carcinoma"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"96. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96(9):e5904-e.","DOI":"10.1097\/MD.0000000000005904"},{"issue":"3","key":"ref96","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/MCG.0b013e3182a8a793","article-title":"Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry","volume":"48","author":"Weinmann","year":"2014","unstructured":"97. Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, K\u00f6nig J, Hoppe-Lotichius M, et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol. 2014;48(3):279-89.","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"ref97","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/medicina55090526","article-title":"Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies","volume":"55","author":"Alqahtani","year":"2019","unstructured":"98. Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas). 2019;55(9):526.","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"ref98","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/hep.26679","article-title":"Fibroblast growth factor signaling in liver carcinogenesis","volume":"59","author":"Sandhu","year":"2014","unstructured":"99. Sandhu DS, Baichoo E, Roberts LR. Fibroblast growth factor signaling in liver carcinogenesis. Hepatology. 2014;59(3):1166-73.","journal-title":"Hepatology"},{"issue":"4","key":"ref99","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3892\/etm.2018.5840","article-title":"Human fibroblast growth factor-21 serves as a predictor and prognostic factor in patients with hepatitis B cirrhosis combined with adrenal insufficiency","volume":"15","author":"Zhang","year":"2018","unstructured":"100. Zhang J, Li J, Ma J, Wang H, Yi Y. Human fibroblast growth factor-21 serves as a predictor and prognostic factor in patients with hepatitis B cirrhosis combined with adrenal insufficiency. Exp Ther Med. 2018;15(4):3189-96.","journal-title":"Exp Ther Med"},{"issue":"4","key":"ref100","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3889\/oamjms.2015.111","article-title":"Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment","volume":"3","author":"Janevska","year":"2015","unstructured":"101. Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3(4):732-6.","journal-title":"Open Access Maced J Med Sci"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/CEG.S173484","article-title":"A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents","volume":"11","author":"El Sagheer","year":"2018","unstructured":"102. El Sagheer GM, Ahmad AK, Abd-ElFattah AS, Saad ZM, Hamdi L. A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents. Clin Exp Gastroenterol. 2018;11:415-22.","journal-title":"Clin Exp Gastroenterol"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"103. Kukla M, Berdowska A, Stygar D, Gabriel A, Mazur W, \u0141ogiewa-Bazger B, et al. Serum FGF21 and RBP4 levels in patients with chronic hepatitis C. Scand J Gastroenterol. 2012;47(8-9):1037-47.","DOI":"10.3109\/00365521.2012.694901"},{"issue":"5","key":"ref103","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans","volume":"57","author":"Zhang","year":"2008","unstructured":"104. Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou Z-G, Liu F, et al. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans. Diabetes. 2008;57(5):1246-53.","journal-title":"Diabetes"},{"issue":"17","key":"ref104","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-20-4219","article-title":"Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study","volume":"27","author":"Finn","year":"2021","unstructured":"105. Finn RS, Kudo M, Cheng A-L, Wyrwicz L, Ngan RK, Blanc J-F, et al. Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study. Clinical Cancer Research. 2021;27(17):4848-58.","journal-title":"Clinical Cancer Research"},{"issue":"22","key":"ref105","doi-asserted-by":"publisher","first-page":"9923","DOI":"10.7150\/thno.45988","article-title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","volume":"10","author":"Zheng Q","year":"2020","unstructured":"106. Zheng Q MR, Shi X, Pandit H, YU Y, Liu X, et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics. 2020;10(22):9923-36.","journal-title":"Theranostics"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molmet.2018.03.002","article-title":"Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet","volume":"13","author":"Singhal G","year":"2018","unstructured":"107. Singhal G KG, Chan S, Fisher FM, Ma y, Vardeh HG, et al. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab. 2018;13:56-66.","journal-title":"Mol Metab"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molmet.2018.03.002","article-title":"Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet","volume":"13","author":"Singhal","year":"2018","unstructured":"108. Singhal G, Kumar G, Chan S, Fisher FM, Ma Y, Vardeh HG, et al. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab. 2018;13:56-66.","journal-title":"Mol Metab"},{"issue":"2","key":"ref108","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.taap.2012.08.003","article-title":"Cobalt chloride decreases fibroblast growth factor-21 expression dependent on oxidative stress but not hypoxia-inducible factor in Caco-2 cells","volume":"264","author":"Liu","year":"2012","unstructured":"109. Liu Y, Wang C, Wang Y, Ma Z, Xiao J, McClain C, et al. Cobalt chloride decreases fibroblast growth factor-21 expression dependent on oxidative stress but not hypoxia-inducible factor in Caco-2 cells. Toxicology and Applied Pharmacology. 2012;264(2):212-21.","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"11","key":"ref109","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","unstructured":"110. Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654-67.","journal-title":"Nat Rev Endocrinol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","unstructured":"111. Tucker B, Li H, Long X, Rye KA, Ong KL. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism. 2019;101:153994.","journal-title":"Metabolism"},{"issue":"12","key":"ref111","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/abbs\/gmu097","article-title":"FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway","volume":"46","author":"Zhu","year":"2014","unstructured":"112. Zhu S, Ma L, Wu Y, Ye X, Zhang T, Zhang Q, et al. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. Acta Biochimica et Biophysica Sinica. 2014;46(12):1041-8.","journal-title":"Acta Biochimica et Biophysica Sinica"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"113. Saswata Talukdar YZ, Dongmei Li, ..., Timothy P. Rolph, Bryan Goodwin, Roberto A. Calle. A Long-Acting FGF21 Molecule, PF-05231023 Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell Metabolism. 2016;23 427-40","DOI":"10.1016\/j.cmet.2016.02.001"},{"issue":"3","key":"ref113","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes","volume":"18","author":"Gaich G","year":"2013","unstructured":"114. Gaich G CJY, Fu H, Glass Leonard C, Deeg Mark A, Holland William L, et al. The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes. Cell Metabolism. 2013;18(3):333-40.","journal-title":"Cell Metabolism"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"115. Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, et al. Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319. PLOS ONE. 2013;8(3):e58575.","DOI":"10.1371\/journal.pone.0058575"},{"issue":"1","key":"ref115","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study","volume":"27","author":"Charles","year":"2019","unstructured":"116. Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity (Silver Spring). 2019;27(1):41-9.","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"ref116","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","unstructured":"117. Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27(7):1262-71.","journal-title":"Nat Med"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"154925","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","unstructured":"118. Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925.","journal-title":"Metabolism"},{"issue":"46","key":"ref118","doi-asserted-by":"publisher","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klothobeta complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","unstructured":"119. Baruch A, Wong C, Chinn LW, Vaze A, Sonoda J, Gelzleichter T, et al. Antibody-mediated activation of the FGFR1\/Klothobeta complex corrects metabolic dysfunction and alters food preference in obese humans. Proc Natl Acad Sci U S A. 2020;117(46):28992-9000.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"120. Depaoli A, Phung V, Bashir MR, Morrow L, Beysen C, Yan A, et al. 140-LB: NGM313, a novel activator of b-Klotho\/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects. Diabetes. 2019;68(Supplement_1).","DOI":"10.2337\/db19-140-LB"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"121. Rader DJ, Maratos-Flier E, Nguyen A, Hom D, Ferriere M, Li Y, et al. LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia. The Journal of Clinical Endocrinology & Metabolism. 2022;107(1):e57-e70.","DOI":"10.1210\/clinem\/dgab624"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"122. Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. 2014;147(5):1073-83. e6.","DOI":"10.1053\/j.gastro.2014.07.044"},{"issue":"3","key":"ref122","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes","volume":"18","author":"Gaich","year":"2013","unstructured":"123. Gaich G, Chien Jenny Y, Fu H, Glass Leonard C, Deeg Mark A, Holland William L, et al. The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes. Cell Metabolism. 2013;18(3):333-40.","journal-title":"Cell Metabolism"},{"issue":"3","key":"ref123","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application","volume":"30","author":"Struik","year":"2019","unstructured":"124. Struik D, Dommerholt MB, Jonker JW. Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. Curr Opin Lipidol. 2019;30(3):235-43.","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"ref124","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","unstructured":"125. Kim AM, Somayaji VR, Dong JQ, Rolph TP, Weng Y, Chabot JR, et al. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes, Obesity and Metabolism. 2017;19(12):1762-72.","journal-title":"Diabetes Obesity and Metabolism"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-nutr-071816-064800","article-title":"Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis","volume":"38","author":"LD","year":"2018","unstructured":"126. BonDurant LD, Potthoff MJ. Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis. Annu Rev Nutr. 2018;38:173-96.","journal-title":"Annu Rev Nutr"},{"issue":"1","key":"ref126","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS\u2010986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study","volume":"27","author":"Charles","year":"2018","unstructured":"127. Charles ED, Neuschwander\u2010Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS, et al. Pegbelfermin (BMS\u2010986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity. 2018;27(1):41-9.","journal-title":"Obesity"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","article-title":"Sustained Brown Fat Stimulation and Insulin Sensitization by a humanized Bispecific Antibody Agonist for Fibroblast Growth Factor receptor 1\/bKlotho Complex","volume":"2","author":"Kolumam","year":"2015","unstructured":"128. Kolumam G. Sustained Brown Fat Stimulation and Insulin Sensitization by a humanized Bispecific Antibody Agonist for Fibroblast Growth Factor receptor 1\/bKlotho Complex. EBioMedicine. 2015;2:730-43.","journal-title":"EBioMedicine"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"129. Rader DJ, Maratos-Flier E, Nguyen A, Hom D, Ferriere M, Li Y, et al. LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. The Journal of Clinical Endocrinology & Metabolism. 2021;107(1):e57-e70.","DOI":"10.1210\/clinem\/dgab624"},{"issue":"11","key":"ref129","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State","volume":"59","author":"fM","year":"2010","unstructured":"130. Fisher fM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State. Diabetes. 2010;59(11):2781-9.","journal-title":"Diabetes"},{"issue":"1","key":"ref130","doi-asserted-by":"publisher","first-page":"30484","DOI":"10.1038\/srep30484","article-title":"Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL\/6J mice","volume":"6","author":"Rusli","year":"2016","unstructured":"131. Rusli F, Deelen J, Andriyani E, Boekschoten MV, Lute C, van den Akker EB, et al. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL\/6J mice. Scientific Reports. 2016;6(1):30484.","journal-title":"Scientific Reports"},{"issue":"1","key":"ref131","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/en.2010-1262","article-title":"Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance","volume":"153","author":"Hale","year":"2012","unstructured":"132. Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology. 2012;153(1):69-80.","journal-title":"Endocrinology"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human","volume":"11","author":"Henriksson","year":"2020","unstructured":"133. Henriksson E, Andersen B. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front Endocrinol (Lausanne). 2020;11:601349.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Turkish Journal of Parasitology"],"original-title":[],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T09:06:16Z","timestamp":1717664776000},"score":1,"resource":{"primary":{"URL":"https:\/\/turkiyeparazitolderg.org\/articles\/doi\/tpd.galenos.2022.14633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":133,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9,12]]},"published-print":{"date-parts":[[2022,9,12]]}},"URL":"https:\/\/doi.org\/10.4274\/tpd.galenos.2022.14633","relation":{},"ISSN":["1300-6320","2146-3077"],"issn-type":[{"value":"1300-6320","type":"print"},{"value":"2146-3077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]}}}